Mark V Sherrid, Milla Arabadjian
Division of Cardiology, St. Luke's-Roosevelt Hospital Center, New York, NY 10019, USA. msherrid@chpnet.org
Progress in cardiovascular diseases 2012 May-JunHypertrophic cardiomyopathy (HCM) occurs in 1 in 500 individuals. Treatment options for HCM differ from those administered in coronary disease, heart failure, and valvular disease patients that comprise the core of many cardiology practices. In this article, we offer a concise summary of the therapeutic use of disopyramide for reducing gradients and relieving symptoms in obstructive HCM. Copyright © 2012 Elsevier Inc. All rights reserved.
Mark V Sherrid, Milla Arabadjian. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Progress in cardiovascular diseases. 2012 May-Jun;54(6):483-92
PMID: 22687589
View Full Text